Literature DB >> 21266501

Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation.

Ting Xie1, Jiurong Liang, Rishu Guo, Ningshan Liu, Paul W Noble, Dianhua Jiang.   

Abstract

The molecular mechanisms of lung injury and fibrosis are incompletely understood. MicroRNAs (miRNAs) are crucial biological regulators that act by suppressing their target genes and are involved in a variety of pathophysiological processes. To gain insight into miRNAs in the regulation of lung fibrosis, total RNA was isolated from mouse lungs harvested at different days after bleomycin treatment, and miRNA array with 1,810 miRNA probes was performed thereafter. MiRNAs expressed in lungs with bleomycin treatment at different time points were compared with miRNAs expressed in lungs without bleomycin treatment, resulting in 161 miRNAs differentially expressed. Furthermore, miRNA expression patterns regulated in initial and late periods after bleomycin were identified. Target genes were predicted in silico for differentially expressed miRNAs, including let-7f, let-7g, miR-196b, miR-16, miR-195, miR-25, miR-144, miR-351, miR-153, miR-468, miR-449b, miR-361, miR-700, miR-704, miR-717, miR-10a, miR-211, miR-34a, miR-367, and miR-21. Target genes were then cross-referenced to the molecular pathways, suggesting that the differentially expressed miRNAs regulate apoptosis, Wnt, Toll-like receptor, and TGF-β signaling. Our study demonstrated a relative abundance of miRNA levels in bleomycin-induced lung fibrosis. The miRNAs and their potential target genes identified may contribute to the understanding of the complex transcriptional program of lung fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266501      PMCID: PMC3110895          DOI: 10.1152/physiolgenomics.00222.2010

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  57 in total

1.  Replication, variation and normalisation in microarray experiments.

Authors:  Naomi Altman
Journal:  Appl Bioinformatics       Date:  2005

Review 2.  Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Paul W Noble; Robert J Homer
Journal:  Am J Respir Cell Mol Biol       Date:  2005-08       Impact factor: 6.914

3.  Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.

Authors:  Nveed I Chaudhary; Andreas Schnapp; John E Park
Journal:  Am J Respir Crit Care Med       Date:  2006-01-13       Impact factor: 21.405

4.  High-dose acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

5.  Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis.

Authors:  K Kuwano; N Hagimoto; M Kawasaki; T Yatomi; N Nakamura; S Nagata; T Suda; R Kunitake; T Maeyama; H Miyazaki; N Hara
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

6.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan.

Authors:  Dianhua Jiang; Jiurong Liang; Juan Fan; Shuang Yu; Suping Chen; Yi Luo; Glenn D Prestwich; Marcella M Mascarenhas; Hari G Garg; Deborah A Quinn; Robert J Homer; Daniel R Goldstein; Richard Bucala; Patty J Lee; Ruslan Medzhitov; Paul W Noble
Journal:  Nat Med       Date:  2005-10-23       Impact factor: 53.440

Review 7.  Idiopathic pulmonary fibrosis: new insights into pathogenesis.

Authors:  Paul W Noble; Robert J Homer
Journal:  Clin Chest Med       Date:  2004-12       Impact factor: 2.878

Review 8.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy.

Authors:  Vuokko L Kinnula; Cheryl L Fattman; Roderick J Tan; Tim D Oury
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

9.  Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis.

Authors:  Erin Addis-Lieser; Jörg Köhl; Mónica G Chiaramonte
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

10.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis.

Authors:  Gang Liu; Arnaud Friggeri; Yanping Yang; Jadranka Milosevic; Qiang Ding; Victor J Thannickal; Naftali Kaminski; Edward Abraham
Journal:  J Exp Med       Date:  2010-07-19       Impact factor: 14.307

View more
  57 in total

Review 1.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

2.  Altered Exosomal RNA Profiles in Bronchoalveolar Lavage from Lung Transplants with Acute Rejection.

Authors:  Aric L Gregson; Aki Hoji; Patil Injean; Steven T Poynter; Claudia Briones; Vyacheslav Palchevskiy; S Sam Weigt; Michael Y Shino; Ariss Derhovanessian; David Sayah; Rajan Saggar; David Ross; Abbas Ardehali; Joseph P Lynch; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

3.  MicroRNA-127 inhibits lung inflammation by targeting IgG Fcγ receptor I.

Authors:  Ting Xie; Jiurong Liang; Ningshan Liu; Qingguo Wang; Yuhang Li; Paul W Noble; Dianhua Jiang
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 4.  Role of microRNAs in the trabecular meshwork.

Authors:  Pedro Gonzalez; Guorng Li; Jianming Qiu; Jing Wu; Coralia Luna
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-02       Impact factor: 2.671

5.  A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.

Authors:  Liqin Du; Robert Borkowski; Zhenze Zhao; Xiuye Ma; Xiaojie Yu; Xian-Jin Xie; Alexander Pertsemlidis
Journal:  RNA Biol       Date:  2013-09-30       Impact factor: 4.652

Review 6.  Emergence of miR-34a in radiation therapy.

Authors:  Jerome Lacombe; Frederic Zenhausern
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-01       Impact factor: 6.312

7.  MicroRNA dysregulation in lung injury: the role of the miR-26a/EphA2 axis in regulation of endothelial permeability.

Authors:  Ryan J Good; Laura Hernandez-Lagunas; Ayed Allawzi; Joanne K Maltzahn; Christine U Vohwinkel; Arun K Upadhyay; Uday B Kompella; Konstantin G Birukov; Todd C Carpenter; Carmen C Sucharov; Eva Nozik-Grayck
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-07-19       Impact factor: 5.464

8.  MicroRNA-144 dysregulates the transforming growth factor-β signaling cascade and contributes to the development of bronchiolitis obliterans syndrome after human lung transplantation.

Authors:  Zhongping Xu; Sabarinathan Ramachandran; Muthukumar Gunasekaran; Fangyu Zhou; Elbert Trulock; Daniel Kreisel; Ramsey Hachem; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2015-03-27       Impact factor: 10.247

9.  Extracellular microRNA signature in chronic kidney disease.

Authors:  Jagdeesan Muralidharan; Ali Ramezani; Monica Hubal; Susan Knoblach; Shashi Shrivastav; Sara Karandish; Richard Scott; Nirmal Maxwell; Savas Ozturk; Srinivasan Beddhu; Jeffrey B Kopp; Dominic S Raj
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-11

10.  MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients.

Authors:  Justin M Long; Balmiki Ray; Debomoy K Lahiri
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.